Harmony Biosciences Q4 2024 net revenue $201.3M, FY $714.7M; guides 2025 $820-860M

Harmony Biosciences Holdings, Inc.

2024-FY EPS reported $2.51 revenue$714,734,000

Q4 2024 net product revenue $201.3M (+20% YoY); FY 2024 net revenue $714.7M (+23% YoY).
Q4 GAAP net income $49.5M ($0.85 diluted EPS); non-GAAP adjusted net income $63.0M ($1.08 diluted EPS).
2025 WAKIX net revenue guidance set at $820M-$860M; on track for potential $1B+ narcolepsy opportunity.
Phase 3 topline for ZYN002 in Fragile X syndrome expected Q3 2025; pitolisant HD trials to start Q4 2025.
Settled first ANDA litigation with Novugen; generic license begins Jan 2030 or earlier under certain conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.